Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.
Alastair Riddell, executive chair of Nuformix, says: "We are pleased to see the progression of the application for the company's first patent in relation to NXP004 to the publication stage. We believe NXP004 has significant potential and look forward to the granting of the Patent in due course. We are continuing to conduct further research and development activities on NXP004, as well as investigating future commercial opportunities."
Current stock price: 0.99 pence
Year-to-date change: down 55%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Nuformix (NFX)